News
UNCY
5.93
-2.31%
-0.14
Unicycive resubmits NDA for hyperphosphatemia asset
Seeking Alpha · 7h ago
Unicycive Therapeutics resubmits NDA for oxylanthanum carbonate
TipRanks · 16h ago
Unicycive Therapeutics Has Resubmitted Its 505(b)(2) New Drug Application To FDA For Oxylanthanum Carbonate For Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis
Benzinga · 16h ago
Unicycive Resubmits NDA for Oxylanthanum Carbonate to FDA
Reuters · 16h ago
UNICYCIVE THERAPEUTICS ANNOUNCES RESUBMISSION OF NEW DRUG APPLICATION (NDA) FOR OXYLANTHANUM CARBONATE (OLC)
Reuters · 16h ago
UNICYCIVE THERAPEUTICS INC - NDA SUBMISSION REVIEW EXPECTED WITHIN 6 MONTHS PER PRESCRIPTION DRUG USER FEE ACT
Reuters · 16h ago
Weekly Report: what happened at UNCY last week (1222-1226)?
Weekly Report · 19h ago
Weekly Report: what happened at UNCY last week (1215-1219)?
Weekly Report · 12/22 09:37
Weekly Report: what happened at UNCY last week (1208-1212)?
Weekly Report · 12/15 09:41
Weekly Report: what happened at UNCY last week (1201-1205)?
Weekly Report · 12/08 09:40
Unicycive Therapeutics unveils new kidney disease treatment pipeline in latest corporate presentation
Reuters · 12/02 20:22
After-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close
NASDAQ · 12/02 04:02
Weekly Report: what happened at UNCY last week (1124-1128)?
Weekly Report · 12/01 09:38
Unicycive Therapeutics to Participate in Piper Sandler Healthcare Conference
Reuters · 11/25 12:05
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
Barchart · 11/25 06:05
Weekly Report: what happened at UNCY last week (1117-1121)?
Weekly Report · 11/24 09:41
Weekly Report: what happened at UNCY last week (1110-1114)?
Weekly Report · 11/17 09:41
Unicycive Therapeutics: Buy Rating Backed by Promising OLC Progress and Strategic Market Positioning
TipRanks · 11/15 16:45
Unicycive Therapeutics Doubles Stock Sale Agreement
TipRanks · 11/14 22:34
UNICYCIVE THERAPEUTICS INC - INCREASES ATM OFFERING TO $100 MLN - SEC FILING
Reuters · 11/14 22:12
More
Webull provides a variety of real-time UNCY stock news. You can receive the latest news about Unicycive Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About UNCY
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.